# AMT-116 in Combination With AK112 in Patients With Lung Cancer

Source: https://onco.cc/trials/nct07590531/  
OnCo record `nct07590531` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Ivonescimab in non-small-cell lung cancer and small-cell lung cancer, run by Multitude Therapeutics Inc., now recruiting.

## Summary

AMT-116 in Combination With AK112 in Patients With Lung Cancer is a phase 1/2 interventional study registered as NCT07590531 by Multitude Therapeutics Inc., with 118 participants planned, started 2026-06-29 and due to reach its primary completion in 2027-05-30. Interventions recorded: AMT-116, AK112. Conditions listed: Advanced Non-small Cell Lung Cancer (NSCLC). No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT07590531
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase Ib/II Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMT116 in Combination With Ivonescimab (AK112) in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)
- Sponsor: Multitude Therapeutics Inc.
- Enrolled: 118

## Sources

- ClinicalTrials.gov NCT07590531: https://clinicaltrials.gov/study/NCT07590531

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- drugs: [AMT-116](https://onco.cc/drugs/amt-116/), [Ivonescimab](https://onco.cc/drugs/ivonescimab/)
- companies: [Multitude Therapeutics](https://onco.cc/companies/multitude-therapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07590531.json